Yu Jianhong's Requirements for Yunnan Peak Year-end Work
Release time:
2020-08-14
Dares to Be True, Responsible, Zero Defects, Promoting Promotion
Yu Jianhong's Request for Yunnan Peak Year-end Work
News Near the end of the year, it is the key period to sprint towards the annual work goal, 12# November 15 , 16 , yu Jianhong, general manager of the group company, went to Yunnan Jianfeng Cement Company to inspect and guide the work. While fully affirming the achievements, he also put forward higher working standards and requirements. In
2017 , Yunnan Peak not only created the best benefits since it was put into production, but also made obvious progress in post integration, process optimization, technological transformation and safety and environmental protection. The safe and civilized production situation on site has been significantly improved, the labor productivity has been significantly improved, and the appearance of the factory has also been greatly improved. Yu Jianhong fully affirmed this.
After listening to the report, going deep into the production site, and understanding the progress of key projects and the completion of economic and technical indicators, Yu Jianhong convened Yunnan peak management cadres to analyze the reasons item by item, discuss improvement measures and implementation plans, and list the rectification time limit, clarify the division of labor, and assign responsibilities to people. He pointed out that the change of an enterprise should start with the management, and the management cadres should have the courage to take responsibility, play the role of the backbone, comprehensively improve their own quality, and then drive the common progress of employees.
Yu Jianhong asked Yunnan Jianfeng cadres and employees to do everything well with the spirit and attitude of "serious" and "serious", keep improving their work and strive to achieve the best. We should start from the source of raw materials entering the factory, strictly implement the quality standards, safety and environmental protection standards of each process, and realize the institutionalization and proceduralization of each work detail; strictly correct and eliminate unsafe behaviors and over-emission disposal at work, make equipment operation and product quality "zero defects", truly achieve high quality, low consumption, and high yield, thereby greatly improving effective productivity; build a modern factory management system and strengthen management The communication between departments, departments, and superiors and subordinates, strengthen the construction of institutionalization and standardization, and improve the effectiveness and sustainability of management; safety production management must not be slack and paralyzed, ensure that every employee can go to work happily and go home safely; strengthen the construction of green factories and create modern cement production enterprises with beautiful environment and green environmental protection. The 30th anniversary of
peak start-up 60# is approaching. Yu Jianhong encourages Yunnan peak cadres and employees to earnestly finish the year of 2017 , make the budget and work plan of 2018 , strive to achieve better results in quality, output and efficiency in the coming year, and present the company's birthday of 60 . (Shi Wenting)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31